Strategic Partnerships Entos is actively collaborating with foundations such as the L-CMD Research Foundation to develop curative therapies for LMNA-Related Congenital Muscular Dystrophy, presenting a clear entry point for academic, patient advocacy, and philanthropy-driven partnerships that can accelerate clinical programs and market access.

Curative Gene Therapy Focus The company emphasizes curative approaches for muscular dystrophies and Duchenne Muscular Dystrophy using Fusogenix PLV delivery, signaling opportunities to engage with rare-disease patient communities, specialty clinics, and gene-editing/development partners seeking durable treatment candidates.

Pipeline Financing With recent venture funding and a revenue range indicative of growing activity, Entos may be receptive to co-development, licensing, or milestone-based funding arrangements to scale preclinical programs and expand manufacturing and regulatory readiness.

Non-viral Delivery Advantage Entos’s Fusogenix PLV platform offers redosable, non-viral delivery of genetic cargo, a differentiator for biotechs and pharma companies pursuing safer regulatory pathways and flexible dosing strategies in genetic medicines and RNA-based therapies.

Strategic Technology Partners Collaborations around Circio circVec vectors and circRNA expression platforms indicate openness to technology licensing or co-development deals that could broaden Entos’s delivery capabilities and create mutual value with collaborators pursuing RNA therapeutics.